antibodi
key
compon
human
adapt
immun
system
elicit
antibodi
correl
vaccin
efficaci
mani
diseas
passiv
infus
antibodi
use
antitoxin
antivir
antiinflammatori
treatment
monoclon
recombin
antibodi
also
current
pursu
prevent
infect
larg
phase
iib
clinic
trial
antibodi
exert
protect
function
via
multitud
mechan
function
neutral
mainli
depend
interact
fv
domain
figur
antigen
therefor
predominantli
fc
domain
independ
function
includ
antibodydepend
cellmedi
cytotox
adcc
antibodydepend
cellular
phagocytosi
adcp
requir
interact
antibodi
fc
domain
protein
immun
effector
cell
via
recognit
fc
receptor
figur
fc
receptordepend
antibodi
function
provid
direct
link
innat
adapt
immun
system
har
potent
antipathogen
function
innat
immun
system
overcom
inher
limit
pattern
recognit
capac
util
divers
specif
adapt
immun
respons
fc
receptordepend
antibodi
function
import
compon
immun
respons
provid
mechan
clearanc
infect
host
cell
immun
complex
opson
pathogen
fc
receptordepend
antibodi
function
also
involv
activ
downstream
adapt
immun
respons
facilit
antigen
present
stimul
secret
inflammatori
mediat
review
focus
antibodi
fc
receptordepend
effector
function
adcp
immun
respons
virus
target
three
area
interest
discuss
biophys
factor
influenc
adcp
includ
properti
receptor
antibodi
effector
cell
survey
interpret
evid
support
potenti
role
adcp
either
inhibit
enhanc
viral
infect
descript
current
approach
use
measur
adcp
consider
translat
studi
perform
anim
model
immun
complex
form
antigen
antibodi
capabl
engag
divers
fc
receptor
innat
immun
cell
type
igg
fc
receptor
activatori
inhibitori
figur
igg
fc
receptor
includ
nonclass
type
ii
igg
fc
receptor
neonat
fcr
fcrn
involv
igg
transport
recycl
cytosol
fc
receptor
iga
antibodi
specif
engag
figur
specif
receptor
ige
involv
rapid
allerg
respons
immun
complex
may
also
interact
receptor
describ
bind
immunoglobulin
rel
uncharacter
includ
fcamr
fcmr
igdr
secretori
compon
receptor
asialoglycoprotein
receptor
cell
receptor
engag
fc
receptor
capabl
cytoplasm
signal
instanc
shown
figur
signal
via
immunoreceptor
tyrosinebas
activ
motif
itam
domain
wherea
lack
itam
domain
associ
signal
chain
signal
via
itam
domain
inhibitori
signal
via
immunoreceptor
tyrosinebas
inhibit
motif
itim
domain
iga
receptor
also
associ
signal
chain
figur
seem
dispens
signal
signal
depend
dephosphoryl
intracellular
domain
downstream
signal
pathway
complex
depend
fc
receptor
cell
type
stimul
mechan
gener
act
via
increas
intracellular
calcium
cation
concentr
activ
pkc
activ
ra
result
ubiquit
presenc
antibodi
system
mucos
microenviron
regulatori
system
requir
prevent
constitut
fc
receptor
signal
achiev
via
sever
mechan
either
intrins
fc
receptor
signal
pathway
impact
extern
solubl
signal
detect
phagocyt
establish
genet
level
figur
key
intrins
regul
inabl
free
antibodi
activ
fc
receptor
signal
lowaffin
fc
receptor
includ
requir
multipl
coordin
interact
suffici
bind
avid
thu
trigger
multival
antibodyantigen
immun
complex
even
highaffin
abl
bind
monomer
igg
bind
trigger
signal
associ
instead
signal
requir
receptor
cluster
crosslink
moreov
activatori
fc
receptor
also
produc
inhibitori
signal
engag
low
mechan
phenomenon
wellunderstood
may
involv
itam
monophosphoryl
activ
inhibitori
rather
diphosphoryl
requir
activatori
syk
engag
similarli
immunostimulatori
immunoinhibitori
fc
receptor
often
coexpress
cell
thu
outcom
antibodymedi
signal
often
depend
balanc
activ
inhibit
signal
abund
receptor
cellsurfac
abil
interact
immun
complex
influenc
solubl
signal
molecul
allow
local
inflammatori
milieu
also
contribut
regul
fc
receptordepend
respons
phagocyt
final
fc
receptor
signal
regul
genet
level
singl
nucleotid
polymorph
human
fc
receptor
affect
interact
antibodi
fc
result
fc
receptor
variant
lower
higher
rel
affin
immun
complex
sever
fc
receptor
polymorph
associ
occurr
progress
diseas
result
infect
virus
includ
dengu
viru
influenza
viru
human
coronaviru
epsteinbarr
viru
ebv
kaposi
sarcoma
viru
ksv
specif
fc
receptor
engag
involv
adcp
differ
virus
virusinfect
cell
site
infect
throughout
antivir
immun
respons
complet
defin
expect
follow
generaliz
rule
describ
follow
section
receptor
involv
differ
depend
characterist
antibodi
form
complex
isotyp
subclass
well
particular
type
phagocyt
encount
immun
complex
addit
fc
receptor
regulatori
mechan
describ
abil
interact
immun
complex
fc
receptor
result
fc
receptor
signal
transduct
regul
specif
characterist
antibodi
fc
region
antibodi
isotyp
serv
princip
level
regul
fc
receptor
specif
one
isotyp
antibodi
within
isotyp
addit
regul
level
antibodi
subclass
figur
human
igg
isotyp
highest
affin
type
follow
contrast
subclass
predomin
sourc
regul
adcp
iga
human
demonstr
similar
affin
addit
regul
receptor
interact
requir
adcp
occur
via
divers
glycosyl
antibodi
fc
igg
fc
region
contain
nlink
glycan
asparagin
figur
impact
conform
antibodi
affin
fc
receptor
describ
comprehens
recent
review
jennewein
alter
igg
antibodi
possibl
glycoform
differ
subclass
yield
total
possibl
uniqu
fc
region
importantli
antibodi
glycovari
modul
inflammatori
respons
allow
immun
system
adapt
adjust
antibodi
fc
glycoform
modul
biolog
activ
respons
infect
chang
antibodi
glycosyl
describ
cours
infect
respons
influenza
vaccin
mani
viral
diseas
role
glycovari
antivir
antibodi
respons
yet
defin
leukocyt
involv
adcp
must
express
least
one
type
fc
receptor
includ
monocyt
macrophag
neutrophil
eosinophil
canon
refer
profession
phagocyt
adcp
phagocyt
engag
antibodi
either
directli
via
fc
receptor
indirectli
via
antibodyfix
complement
engulf
one
opson
particl
molecul
typic
includ
pathogen
infect
cell
deriv
intern
case
lead
destruct
intern
target
phagolysosom
degrad
though
import
note
sever
human
pathogen
evolv
coopt
process
surviv
within
phagocyt
phagocytosi
lead
differ
immun
outcom
depend
cell
instanc
antibodymedi
phagocytosi
macrophag
lead
enhanc
pathogen
destruct
antigen
present
wherea
antibodymedi
phagocytosi
plasmacytoid
dendrit
cell
lead
enhanc
secret
interferon
alpha
fc
receptormedi
phagocytosi
ligat
aggreg
fc
receptor
becom
phosphoryl
via
src
famili
tyrosin
kinas
itam
domain
either
associ
form
dock
site
syk
trigger
signal
cascad
involv
pkc
synthesi
pi
dag
lead
actin
cytoskeleton
remodel
allow
advanc
phagocyt
cell
target
strength
earli
signal
event
proport
number
engag
fc
receptor
wherea
late
signal
event
requir
complet
phagocytosi
requir
concentr
threshold
satisfi
type
phagocyt
involv
adcp
respons
viru
infect
depend
profil
fc
receptor
express
cell
characterist
antivir
antibodi
describ
also
phagocyt
present
recruit
site
infect
profession
phagocyt
differenti
distribut
circul
tissu
inflammatori
signal
promot
ingress
egress
immun
effector
cell
therefor
cell
present
site
infect
involv
antivir
respons
like
chang
time
transgen
mous
model
celltyp
specif
deplet
help
identifi
essenti
cell
popul
clear
view
specif
interact
involv
tissu
site
viru
infect
often
limit
especi
human
despit
difficulti
inher
access
studi
immun
cell
situ
within
human
tissu
remark
studi
sip
et
al
defin
distribut
frequenc
fc
receptor
express
immun
cell
mucos
lymphoid
tissu
identifi
differenti
distribut
profession
phagocyt
macrophag
domin
phagocyt
popul
lymph
node
intestin
tissu
neutrophil
repres
domin
phagocyt
popul
tissu
lower
femal
reproduct
tract
use
novel
tissu
phagocytosi
assay
compar
adcp
activ
neutrophil
macrophag
colon
cervix
found
although
abund
colon
colonresid
macrophag
defici
adcp
compar
colon
cervixresid
neutrophil
well
cervixresid
macrophag
semin
studi
like
partial
defin
divers
profession
phagocyt
phenotyp
function
within
tissu
encount
antibodyviru
immun
complex
viru
infect
inevit
impact
outcom
encount
importantli
phagocyt
capabl
fcdepend
effector
function
addit
adcp
thu
outcom
interact
phagocyt
immun
complex
determin
combin
signal
figur
mani
phagocyt
express
one
type
fc
receptor
often
express
activatori
inhibitori
fc
receptor
balanc
diverg
signal
pathway
critic
simul
regul
potenti
effector
respons
signal
mediat
type
receptor
also
contribut
determin
type
effector
respons
phagocyt
mount
among
inform
pattern
recognit
receptor
prr
detect
molecular
patter
associ
differ
type
pathogen
integr
respons
fc
receptor
stimuli
exampl
tolllik
receptor
abil
detect
viral
nucleic
acid
activ
immun
cell
therefor
abl
potenti
effect
antivir
respons
includ
adcp
contrast
altern
inhibitori
signal
neg
regul
phagocytosi
intriguingli
virus
express
homologu
may
act
prevent
activ
profession
phagocyt
strategi
immun
evas
apart
direct
antivir
activ
uptak
elimin
viru
infect
cell
antibodydepend
phagocytosi
also
import
develop
regul
immun
respons
figur
pathogenassoci
molecular
pattern
pamp
deriv
viru
antigen
releas
upon
phagocytosi
digest
immun
complex
releas
viru
pamp
prime
inflammatori
respons
upon
sens
prr
may
stimul
addit
immun
cell
activ
subsequ
immun
respons
instanc
adenoviru
infect
respiratori
tract
alveolar
macrophag
respons
intern
adenoviru
initi
earli
proinflammatori
signal
similar
respons
term
antibodyinduc
inflamm
demonstr
import
role
protect
influenza
infect
also
direct
role
adcp
modul
adapt
immun
adcp
immun
complex
dendrit
cell
via
promot
mhc
class
ii
antigen
present
induc
cellular
humor
immun
respons
uptak
prevent
dendrit
cell
matur
promot
immun
activ
antibodi
product
affin
also
regul
induct
bcell
apoptosi
help
elimin
b
cell
low
affin
b
cell
receptor
base
divers
role
adcp
immun
respons
unsurpris
adcp
shown
import
compon
immun
respons
infect
mani
differ
virus
context
natur
infect
first
line
evid
role
adcp
antivir
immun
respons
associ
fc
receptor
genet
diseas
progress
risk
infect
forthal
collabor
perform
genotyp
larg
cohort
infect
men
n
enter
studi
prior
avail
antiretrovir
therapi
enrol
cohort
cell
count
found
homozygos
low
affin
allel
fc
receptor
implic
iggmedi
adcp
activ
antibodi
respons
significantli
predict
acceler
rate
diseas
progress
cell
count
compar
subject
heterozyg
allel
homozyg
high
affin
allel
correl
observ
allel
variant
convent
regard
primari
fc
receptor
involv
natur
killer
nk
cell
adcc
associ
fc
receptor
genet
risk
infect
also
studi
set
vertic
transmiss
use
sampl
collect
hivseroposit
mother
pair
infant
western
kenya
brouwer
et
al
identifi
infant
homozygos
high
affin
allel
risk
factor
perinat
infect
observ
impact
matern
allel
transmiss
recent
similar
studi
conduct
use
sampl
collect
transmit
mother
nontransmit
mother
offspr
south
african
cohort
contrast
result
latter
studi
infant
acquisit
risk
factor
identifi
brouwer
et
al
recapitul
instead
author
report
mother
high
affin
allel
homozyg
heterozyg
associ
significantli
lower
risk
vertic
transmiss
taken
collect
three
observ
highlight
complex
interpret
correl
studi
seemingli
contradictori
find
explain
mani
factor
like
contribut
diverg
outcom
includ
differenti
requir
immun
control
diseas
progress
vs
infect
compar
forthal
studi
two
studi
investig
vertic
transmiss
within
transmiss
studi
author
south
african
studi
put
forth
hypothesi
differ
timepoint
use
determin
hiv
infect
may
result
inclus
postnat
breastfeed
transmiss
event
brouwer
studi
like
differ
requir
protect
compar
infect
occur
utero
perinat
although
may
case
also
import
reiter
fc
receptor
genet
one
level
regul
adcp
fc
receptordepend
immun
respons
previous
describ
regul
occur
level
cell
type
phagocyt
combin
receptor
express
within
tissu
immun
environ
presenc
absenc
inflammatori
signal
via
antibodi
compris
immun
complex
specif
isotyp
subclass
glycoform
thu
although
studi
base
genet
factor
alon
may
provid
insight
potenti
adcp
fc
receptordepend
antibodi
function
contribut
immun
respons
limit
inabl
account
myriad
factor
impact
antibodi
effector
function
vivo
studi
help
address
limit
provid
addit
evid
adcp
play
import
antivir
role
compar
adcp
activ
polyclon
igg
collect
infect
individu
healthi
control
ackerman
collabor
determin
phagocytosi
activ
higher
igg
virem
patient
control
compar
igg
collect
patient
highli
activ
antiretrovir
therapi
importantli
found
antibodi
control
abl
outcompet
phagocyt
activ
antibodi
virem
individu
bias
toward
interact
activatori
interact
inhibitori
followup
studi
demonstr
adcp
compon
polyfunct
respons
control
includ
nk
cell
activ
adcc
complement
deposit
like
impact
skew
antibodi
glycoform
unlik
observ
hiv
control
impair
phagocytosi
one
hallmark
chronic
virem
infect
may
relat
loss
express
monocyt
dendrit
cell
preclin
clinic
trial
candid
vaccin
provid
opportun
evalu
import
adcp
protect
infect
immun
correl
analys
suggest
protect
infect
well
inhibit
viru
replic
establish
infect
mediat
direct
neutral
also
fcmediat
antibodi
effector
function
rhesu
macaqu
siv
shiv
preclin
anim
model
nonbroadli
neutral
antibodi
function
includ
phagocytosi
correl
reduc
risk
infect
measur
increas
number
lowdos
challeng
infect
particular
interest
eleg
studi
ackerman
colleagu
identifi
distinct
immun
signatur
vaccinemedi
protect
depend
rout
immun
studi
rhesu
macaqu
immun
dna
envbas
vaccin
regim
either
via
intramuscular
im
rout
intranas
aerosol
ae
formul
equival
level
vaccin
efficaci
repeat
low
dose
intrarect
challeng
observ
im
ae
immun
group
although
uniqu
humor
immun
profil
correl
risk
identifi
adcp
howev
identifi
correl
reduc
infect
risk
im
ae
vaccin
group
remark
although
adcp
common
immun
function
link
protect
independ
rout
immun
phagocyt
antibodi
isotyp
associ
adcp
differ
anim
vaccin
im
rout
monocyt
adcp
igg
associ
reduc
risk
infect
adcp
neutrophil
term
antibodydepend
neutrophil
phagocytosi
adnp
iga
associ
reduc
risk
infect
anim
vaccin
via
ae
rout
importantli
cross
studi
valid
adcp
correl
preform
adcp
also
identifi
associ
reduc
risk
infect
low
dose
shiv
challeng
rhesu
macaqu
vaccin
alvac
prime
vaccin
regimen
provid
evid
adcp
vaccineelicit
protect
afford
differ
vaccin
regimen
rout
inocul
differ
challeng
virus
consist
observ
efficaci
preclin
studi
perform
rhesu
macaqu
model
immun
correl
analysi
partial
efficaci
vaccin
human
clinic
trial
provid
evid
nonneutr
antibodi
contribut
reduc
risk
infect
vaccineelicit
variabl
region
igg
antibodi
correl
decreas
risk
infect
antibodi
broadli
neutral
capabl
multipl
antivir
function
adcc
virion
captur
adcp
neutral
notabl
vaccin
regimen
elicit
antibodi
exhibit
coordin
fcmediat
effector
respons
fc
receptor
polymorph
also
influenc
vaccin
efficaci
although
polymorph
associ
adcp
vaccin
efficaci
trial
show
efficaci
either
lack
coordin
fc
receptordepend
effector
respons
lack
evid
strong
fcmediat
antibodi
function
consid
collect
result
nonhuman
primat
candid
vaccin
clinic
trial
provid
strong
evid
adcp
achiev
potenti
protect
antivir
immun
respons
induc
prevent
vaccin
effort
continu
toward
develop
vaccin
induc
broadneutr
antibodi
import
ensur
adcp
fc
receptordepend
antibodi
respons
elicit
fortun
although
broadli
neutral
antibodi
bnab
defin
base
abil
neutral
broad
rang
virus
mani
bnab
also
capabl
mediat
fc
receptordepend
antivir
function
includ
adcc
adcp
passiv
immun
trial
also
show
antibodymedi
protect
activ
sole
due
neutral
also
part
due
fc
receptordepend
function
nonhuman
primat
nhp
passiv
immun
studi
high
low
dose
vagin
challeng
rhesu
macaqu
protect
decreas
administ
passiv
antibodi
incap
bind
fc
receptor
similarli
passiv
immun
studi
perform
human
mice
antibodi
enhanc
abil
bind
activ
fc
receptor
gave
greater
protect
epitopematch
counterpart
although
specif
role
adcp
observ
determin
combin
evid
provid
studi
viru
control
diseas
progress
candid
vaccin
trial
strong
evid
support
adcp
contribut
antibodymedi
protect
howev
recent
studi
parson
collabor
demonstr
highli
potent
neutral
antibodi
fcreceptor
depend
function
dispens
maxim
protect
result
suggest
extent
fc
receptordepend
antibodi
function
contribut
protect
variabl
like
depend
multipl
factor
includ
neutral
potenc
andor
characterist
viru
challeng
huber
colleagu
use
murin
vaccin
challeng
model
provid
evid
support
role
adcp
protect
immun
respons
influenza
viru
infect
normal
balbc
mice
balbc
mice
engin
lack
express
fc
receptor
thu
defici
fc
receptor
given
ident
influenza
immun
challeng
mice
lack
fc
receptor
incap
antibodymedi
phagocytosi
highli
suscept
influenza
infect
despit
presenc
normal
level
cytokin
antibodi
condit
revers
even
presenc
passivelyinfus
antiinfluenza
antibodi
immun
wild
type
mice
indic
defect
interact
antibodi
immun
effector
cell
caus
suscept
effector
mechan
narrow
demonstr
protect
passiv
transfer
immun
sera
mice
lack
cell
nk
cell
therebi
show
lack
depend
nk
cell
suggest
adcc
mechan
inhibit
contrast
macrophag
observ
ingest
opson
viru
particl
implic
adcp
inhibit
influenza
infect
subsequ
work
demonstr
neutrophil
may
essenti
phagocyt
interact
influenza
specif
antibodi
protect
diseas
anoth
line
evid
show
deplet
lung
phagocyt
ie
neutrophil
alveolar
macrophag
caus
uncontrol
growth
influenza
mice
caus
mortal
dose
subleth
normal
mice
passiv
immun
studi
perform
normal
mice
neutrophildeplet
mice
demonstr
effector
mechan
respons
control
influenza
infect
phagocyt
like
antibodydepend
sinc
control
infect
enhanc
passiv
infus
antiserum
consist
result
delillo
collabor
use
human
receptor
mice
passiv
immun
model
demonstr
influenza
hemagglutinin
protein
stalkspecif
neutral
human
monoclon
antibodi
see
epitop
section
depend
interact
activatori
receptor
protect
influenza
challeng
antivir
mechan
protect
found
like
depend
adcc
adcp
passiv
immun
experi
perform
collabor
second
studi
dilillo
collabor
also
demonstr
requir
fc
receptor
interact
order
achiev
maxim
protect
neutral
nonneutr
influenzaspecif
antibodi
collabor
found
protect
depend
alveolar
macrophag
cell
capabl
adcp
immun
complex
form
influenza
viru
nonneutr
neutral
antibodi
suggest
role
adcp
observ
protect
efficaci
passiv
immun
contribut
adcp
protect
influenza
infect
observ
passiv
immun
studi
support
antibodi
capabl
adcp
desir
outcom
activ
immun
protect
influenza
infect
paramount
goal
armamentarium
influenza
pandem
develop
univers
vaccin
efficaci
high
divers
influenza
subtyp
strain
variant
result
antigen
drift
mani
approach
toward
goal
attempt
focu
immun
respons
highli
conserv
influenza
antigen
result
test
candid
vaccin
regimen
suggest
adcp
may
import
immun
respons
elicit
antibodi
target
conserv
influenza
epitop
use
influenza
viru
like
particl
vlp
immunogen
elicit
respons
highli
conserv
matrix
protein
song
colleagu
demonstr
mice
vlp
immun
sera
induc
cross
protect
across
heterolog
influenza
virus
includ
pandem
viru
well
heterosubtyp
influenza
virus
also
found
immun
sera
respons
crossprotect
requir
presenc
dendrit
cell
macrophag
anoth
group
independ
identifi
similar
observ
reach
similar
conclus
use
vaccin
approach
base
conserv
influenza
epitop
show
passiv
immun
antibodi
depend
presenc
alveolar
macrophag
intact
immun
protect
author
studi
point
protein
highli
express
surfac
infect
cell
limit
influenza
virion
therefor
hypothes
antibodi
preferenti
target
influenza
infect
cell
elimin
via
adcc
adcp
prior
viru
propag
releas
bud
adcp
infect
cell
understudi
aspect
immun
respons
viral
infect
investig
context
collect
preclin
candid
vaccin
studi
provid
evid
protect
fc
receptordepend
process
includ
adcp
may
broad
stretch
across
influenza
subtyp
howev
adcp
activ
also
shown
compon
noncrossreact
immun
respons
induc
season
trival
influenza
vaccin
antiinfluenza
sera
adcp
activ
common
healthi
adult
remain
unknown
adcp
fc
receptordepend
function
contribut
persist
natur
vaccineinduc
respons
season
influenza
evid
studi
perform
anim
model
suggest
phagocyt
adcp
contribut
protect
immun
respons
influenza
viru
may
also
aspect
function
augment
influenza
infect
exampl
inhibit
remov
abil
phagocyt
produc
reactiv
oxygen
speci
improv
resolut
lung
influenza
infect
mice
high
affin
allel
found
risk
factor
sever
pneumonia
pandem
adcp
herp
simplex
virusinfect
fibroblast
neutrophil
monocyt
observ
vitro
sever
studi
implic
adcp
role
immun
respons
herpesviru
infect
adcp
recent
identifi
compon
antibodi
respons
elicit
vaccin
cytomegaloviru
cmv
subunit
vaccin
nelson
collabor
investig
humor
compon
reduc
risk
cmv
acquisit
observ
moder
efficaci
clinic
trial
cmv
glycoprotein
vaccin
conduct
postpartum
women
consist
previou
observ
found
vaccin
induc
modest
neutral
antibodi
respons
howev
vaccineelicit
antibodi
demonstr
bind
surfac
infect
cell
mediat
robust
adcp
gbprotein
coat
bead
fluorescentlylabel
whole
cmv
virion
interestingli
vaccin
elicit
high
magnitud
gbspecif
respons
like
contribut
high
level
adcp
observ
isotyp
previous
shown
superior
virion
adcp
studi
perform
studi
nelson
et
al
novel
implic
nonneutr
antibodi
respons
import
role
antibodi
respons
cmv
therefor
may
help
open
new
pathway
toward
develop
highli
effect
nextgener
cmv
vaccin
genet
link
provid
evid
role
adcp
immun
respons
herpesvirus
describ
ebv
low
affin
allel
found
enrich
ebv
infect
correl
express
latenc
protein
suggest
allel
may
risk
factor
latent
ebv
infect
collect
studi
provid
evid
adcp
contribut
vaccineelicit
natur
immun
respons
herpesviru
infect
due
preval
herpesvirus
worldwid
need
addit
strategi
treatment
prevent
addit
research
area
warrant
although
adcp
comprehens
studi
context
viru
infect
may
common
compon
antivir
humor
immun
respons
divers
type
virus
support
studi
respiratori
syncyti
viru
rsv
ebola
viru
human
papilloma
viru
hpv
footandmouth
diseas
viru
fmdv
sever
acut
respiratori
syndrom
coronaviru
sarscov
west
nile
viru
wnv
rsv
ebola
viru
evid
adcp
immun
respons
limit
vitro
assess
virusspecif
monoclon
antibodi
adcc
adcp
activ
observ
rsv
g
proteinspecif
monoclon
antibodi
produc
b
cell
healthi
presum
rsv
expos
immun
adult
ebola
viru
glycoproteinspecif
monoclon
antibodi
produc
b
cell
respons
ebola
viru
glycoprotein
dna
prime
virusvector
boost
vaccin
shown
adcp
activ
contribut
adcp
activ
protect
hpv
infect
report
antihpv
neutral
monoclon
antibodi
use
passiv
transfer
experi
mous
model
wang
collabor
provid
evid
hpvspecif
igg
monoclon
antibodi
cross
vagin
epitheli
site
local
disrupt
igg
adcp
activ
propos
adcp
augment
protect
vagin
hpv
infect
result
viru
neutral
protect
less
efficaci
passiv
transfer
perform
f
instead
whole
igg
perform
mice
mice
deplet
neutrophil
macrophag
genotyp
peopl
previous
infect
sarscov
regionmatch
normal
donor
use
identifi
homozygos
low
affin
allel
significantli
associ
sever
sarscov
infect
evid
support
role
adcp
immun
respons
attenu
sarscov
infect
come
deplet
studi
demonstr
requir
infiltr
tissu
resid
macrophag
well
sar
immun
sera
clearanc
sarscov
pulmonari
cell
mous
model
nk
cell
requir
suggest
adcc
immun
mechan
involv
reduct
infect
sar
immun
sera
use
experi
abil
neutral
sarscov
thu
studi
provid
anoth
exampl
adcp
contribut
protect
mediat
antibodi
abil
neutral
viru
describ
hpv
similar
observ
made
fmdv
taken
togeth
observ
suggest
compel
possibl
mani
virus
neutral
shown
abil
prevent
control
infect
adcp
fc
receptordepend
effector
function
may
also
contribut
enhanc
protect
function
extent
yet
fulli
defin
wnv
passiv
antibodi
transfer
wnv
nonstructur
specif
monoclon
antibodi
normal
mice
receptor
knockout
mice
demonstr
fc
receptordepend
protect
protect
maintain
mice
lack
suggest
nk
cell
adcc
essenti
author
demonstr
murin
macrophag
abl
intern
target
cell
presenc
antibodi
gener
hypothesi
adcp
contribut
protect
wnv
infect
model
system
interestingli
studi
demonstr
role
adcp
virusinfect
cell
protect
understudi
compar
adcp
whole
viru
viru
protein
possibl
infectedcel
virion
adcp
may
context
diverg
contribut
antivir
respons
shown
virion
adcp
promot
higher
replic
wnv
flavivirus
use
vitro
cell
cultur
model
adcp
alway
associ
benefici
protect
immun
respons
case
adcp
demonstr
promot
infect
term
antibodydepend
enhanc
ade
predominantli
describ
virus
genu
flaviviru
includ
dengu
viru
yellow
fever
viru
japanes
enceph
viru
zika
viru
fc
receptordepend
ade
particular
concern
infect
dengu
viru
four
serotyp
dengu
viru
antibodi
gener
respons
infect
one
serotyp
variabl
degre
cross
reactiv
three
serotyp
upon
rechalleng
origin
serotyp
antibodi
protect
howev
preexist
antibodi
respons
augment
infect
promot
sever
diseas
upon
secondari
infect
serotyp
moreov
ade
result
cross
reactiv
may
limit
secondari
infect
anoth
strain
viru
ade
might
also
occur
secondari
infect
differ
close
relat
viru
exampl
result
recent
studi
suggest
dengu
virusspecif
antibodi
may
capabl
enhanc
zika
viru
infect
reciproc
zika
virusspecif
antibodi
may
capabl
enhanc
dengu
viru
infect
observ
met
skeptic
addit
work
requir
demonstr
type
ade
clinic
relev
dengu
zika
incid
diseas
ade
thought
occur
nonneutr
antibodi
suboptim
concentr
neutral
antibodi
bind
opson
viru
subsequ
intern
fc
receptor
express
cell
via
adcp
within
cell
immun
complex
may
perturb
normal
antivir
immun
function
result
viru
destroy
instead
viru
exploit
adcp
tool
expand
access
host
cell
result
higher
infect
burden
often
stimul
overt
inflammatori
respons
contribut
diseas
pathogenesi
virus
dengu
subvert
process
adcp
promot
increas
infect
one
potenti
mechan
propos
allow
dengu
viru
escap
fc
receptormedi
antivir
signal
engag
inhibitori
receptor
leukocyt
immunoglobulinlik
thu
dengu
virus
outcom
interact
antibodyviru
immun
complex
phagocyt
depend
balanc
activ
signal
expect
promot
adcp
viru
elimin
inhibitori
signal
potenti
enhanc
infect
studi
infect
earli
paper
report
complement
antibodi
low
titer
could
enhanc
infect
vitro
sinc
monocyt
macrophag
infect
one
theori
antibodymedi
phagocytosi
may
caus
increas
viral
infect
phagocyt
specif
enhanc
may
due
sole
weakli
nonneutr
antibodi
remain
capabl
engag
neutral
viru
howev
notabl
enhanc
infect
vaccin
arm
observ
clinic
trial
elicit
high
level
nonneutr
antibodi
describ
comprehens
review
topic
taylor
collabor
evid
ade
mani
virus
includ
influenza
sarscov
rsv
ebola
also
exist
evid
adcp
part
benefici
antivir
antibodi
respons
dichotom
observ
emphas
balanc
act
face
immun
system
attempt
respond
viru
infect
immun
respons
suffici
specif
potenc
requir
protect
infect
diseas
suboptim
respons
exploit
pathogen
result
higher
level
infect
sever
diseas
ade
remain
concern
develop
vaccin
virus
potent
neutral
antibodi
respons
elicit
one
best
exampl
epitop
specif
impact
adcp
describ
influenzaspecif
antibodi
two
distinct
epitop
region
influenza
hemagglutinin
protein
recogn
influenzaspecif
antibodi
immunodomin
antigen
variabl
head
domain
antigen
conserv
stalk
region
figur
dilillo
colleagu
demonstr
requir
receptor
interact
protect
stalkspecif
antibodi
antibodi
recogn
head
domain
demonstr
stalkspecif
antibodi
capabl
activ
nk
cell
adcc
protect
efficaci
stalkspecif
antibodi
could
improv
mutat
select
enhanc
engag
mullarkey
colleagu
followedup
insight
identifi
similar
epitopedepend
dichotomi
antihemagglutinin
antibodi
respons
antivir
assay
perform
neutrophil
sourc
innat
effector
cell
use
recombinantlyproduc
chimer
antibodi
mous
fv
human
fc
region
demonstr
stalkspecif
headspecif
antibodi
induc
adcp
reactiv
oxygen
product
neutrophil
similar
observ
made
antibodi
made
iga
indic
epitop
dichotomi
interact
fc
receptor
conserv
receptor
use
recombinantli
produc
antibodi
ident
fc
region
confirm
least
influenza
viru
antibodi
epitop
specif
play
essenti
role
establish
downstream
antivir
effector
respons
subsequ
studi
dilillo
collabor
expand
upon
initi
observ
demonstr
requir
fc
receptor
involv
protect
vivo
restrict
stalkspecif
antibodi
instead
common
featur
antibodi
capabl
recogn
breadth
influenza
strain
use
mous
model
fc
receptor
depend
protect
shown
broadli
neutral
stalk
head
specif
antibodi
well
broadlybind
nonneutr
headspecif
antibodi
thu
exist
yet
explain
relationship
breadth
fc
receptordepend
protect
antibodi
respons
influenza
sera
human
donor
abil
mediat
antiinfluenza
adcp
therefor
import
futur
research
map
specif
natur
human
influenza
adcp
antibodi
explain
mechan
underli
differenti
function
strainspecif
head
antibodi
multistrain
specif
head
stalk
antibodi
similar
epitop
dichotomi
describ
ebola
viru
ebola
viru
envelop
glycoprotein
similar
envelop
fusion
glycoprotein
influenza
share
common
architectur
trimer
dimer
protein
dimer
compris
distal
receptorbind
head
region
membranebound
stemstalk
region
figur
stemstalk
region
less
variabl
head
region
howev
head
region
gener
regard
immunodomin
ebola
stalkspecif
specif
antibodi
demonstr
capabl
mediat
multipl
fc
receptordepend
effector
function
includ
nk
cell
activ
adcp
monocyt
neutrophil
glycan
capspecif
mab
lack
function
thu
interest
studi
parallel
differ
broadbind
influenza
ebolaviru
stalkspecif
adcp
antibodi
biomolecular
interact
underli
relationship
epitop
function
elucid
divers
epitop
target
virion
phagocytosi
includ
broadli
neutral
epitop
mper
stem
region
headregion
target
bind
site
glycan
trimer
apex
nonbroadli
neutral
epitop
princip
immunodomin
domain
stem
region
loop
loop
head
region
also
target
adcp
antibodi
epitop
found
hivinfect
cell
engag
alon
phagocytosi
engag
synergist
least
epitop
viru
engag
abil
epitop
engag
phagocytosi
vari
strain
indic
substanti
heterogen
virus
furthermor
antibodi
target
epitop
vari
phagocytosi
potenc
emphas
fact
rule
antibodyepitop
engag
allow
adcp
complet
understood
may
includ
antibodi
fc
avail
affect
antigen
bind
valenc
angl
approach
also
like
nonneutr
antigen
target
virion
surfac
involv
adcp
fcdepend
function
discov
understand
envelop
protein
env
surfac
strongli
bias
toward
neutral
epitop
sinc
search
antibodi
typic
involv
select
character
antibodi
posit
neutral
howev
typic
make
portion
antibodi
elicit
respons
infect
vaccin
nonneutr
specif
capabl
bind
engag
env
typic
studi
addit
monomer
protein
even
current
gener
stabil
trimer
protein
typic
use
hook
antibodi
select
like
fulli
recapitul
divers
natur
env
form
virion
envelop
may
includ
function
trimer
nonfunct
form
envelop
largescal
unbias
antibodi
screen
may
identifi
addit
crucial
antibodi
specif
fcmediat
effector
function
virion
may
target
vaccin
passiv
immunotherapi
import
note
virion
adcp
method
differenti
infecti
noninfecti
virion
open
question
remain
whether
nonneutr
antibodi
appear
mediat
viru
adcp
inde
caus
uptak
infecti
virus
whether
mere
engag
noninfecti
epitop
defect
particl
virusinfect
cell
virion
particl
distinct
biolog
target
antibodymedi
intern
epitop
specif
involv
process
may
differ
given
differ
epitop
exposur
virus
infect
cell
instanc
context
princip
immunodomin
domain
target
antibodi
frequent
found
virion
infect
cell
wherea
convers
true
conserv
region
conform
domain
target
antibodi
major
studi
describ
adcp
respons
focus
protein
whole
virion
thu
much
less
known
adcp
infect
cell
epitop
may
involv
process
addit
research
area
need
virus
compar
less
describ
regard
fine
epitop
specif
adcp
antibodi
immun
respons
viru
infect
vaccin
gener
rule
adcp
virion
epitop
must
present
surfac
virion
adcp
infect
cell
epitop
express
surfac
virusinfect
cell
may
potenti
target
virus
limit
antibodi
specif
describ
mediat
adcp
cmv
gb
protein
rsv
g
protein
ebola
viru
glycoprotein
hpv
protein
wnv
protein
studi
adcp
activ
identifi
test
avail
antibodi
antibodi
select
altern
function
neutral
therefor
mani
potenti
specif
remain
unexplor
like
antibodi
target
epitop
region
capabl
adcp
activ
yet
identifi
overal
dearth
knowledg
regard
specif
epitop
target
adcp
antibodi
virus
insight
area
may
inform
new
strategi
ration
design
vaccin
intend
elicit
adcp
respons
viru
adcp
typic
measur
via
cellbas
assay
amount
viral
target
intern
phagocyt
quantifi
sampl
monoclon
polyclon
antibodi
first
premix
viral
target
form
immun
complex
phagocyt
introduc
antibodydepend
phagocytosi
occur
phagocyt
includ
primari
monocyt
macrophag
neutrophil
correspond
cell
line
phagocyt
spinocul
immun
complex
increas
signaltonois
ratio
though
necessari
achiev
detect
signal
case
antibodydepend
phagocytosi
virion
nonintern
viru
particl
wash
amount
intern
viral
target
quantifi
theori
method
capabl
quantifi
target
particl
eg
nucleicacid
base
rtpcr
proteinbas
elisa
fluoresc
use
assay
readout
long
intern
viru
particl
separ
extracellular
cellattach
particl
practic
fluorescencebas
approach
popular
due
capabl
highthroughput
readout
via
flow
cytometri
fluorescencebas
approach
target
particl
could
live
fluorescentlylabel
virion
virusderiv
protein
conjug
fluoresc
bead
virion
label
done
direct
label
includ
viral
membran
label
would
exclud
detect
membranefus
virus
intern
label
via
cotransfect
gene
encod
fluoresc
nonstructur
protein
result
random
incorpor
packag
viru
particl
fluoresc
label
also
engin
report
intern
either
addit
noncellperm
fluoresc
quencher
wash
step
use
phsensit
dye
yet
unclear
result
compar
differ
type
viral
target
notabl
phagocytosi
signal
pathway
particl
uptak
dynam
impact
physic
properti
target
includ
ligand
space
size
shape
stiff
antigen
height
sinc
viru
particl
differ
proteinco
bead
number
attribut
remain
unclear
differ
affect
fcfc
receptor
signal
influenc
rang
viru
epitopefab
conform
capabl
mediat
phagocytosi
case
one
group
argu
viru
particl
undergo
adcp
due
insuffici
surfac
ligand
densiti
base
observ
undetect
intern
virus
hivspecif
antibodi
compar
antiphosphatidylserin
antibodi
howev
result
odd
work
demonstr
epitopespecif
intern
viru
particl
use
varieti
hivspecif
monoclon
antibodi
differ
env
specif
well
polyclon
antibodi
sera
breast
milk
sinc
experiment
procedur
use
group
similar
reason
discrep
unclear
may
involv
method
viru
prepar
move
forward
import
determin
natur
immun
complex
affect
phagocytosi
current
assay
routin
measur
size
immun
complex
engulf
number
intracellular
intravesicular
virion
may
either
singl
immun
complex
amalgam
multipl
cophagocytos
virus
fact
mani
virus
even
clear
whether
antibodydepend
virion
intern
strictli
process
phagocytosi
whether
process
includ
endocytosi
macropinocytosi
involv
also
import
determin
signal
outcom
phagocytosi
multipl
cell
type
inflammatori
condit
order
determin
role
phagocytosi
recruit
effector
function
well
subsequ
develop
local
inflammatori
respons
longer
term
adapt
immun
prime
highli
polymorph
virus
includ
influenza
also
use
develop
panel
repres
viral
strain
fluoresc
necessari
use
reproduc
measur
breadth
adcp
activ
compar
across
differ
set
clinic
trial
inde
antibodi
neutral
potenc
tier
virus
necessarili
predict
neutral
breadth
adcp
breadth
may
provid
surpris
clue
develop
vaccin
elicit
strong
fc
effector
function
contrast
adcp
viru
particl
methodolog
adcp
virusinfect
cell
remain
underexplor
current
adcp
assay
develop
measur
intern
immun
complex
form
virion
proteinco
bead
thu
remain
difficult
quantifi
antibodi
epitop
specif
fc
profil
contribut
toward
potenc
adcp
virusinfect
cell
methodolog
investig
adcp
virusinfect
cell
vitro
vivo
particular
differenti
event
nonantibodymedi
phagocytosi
virusinfect
cell
also
import
determin
whether
infectedcel
adcp
result
viru
inhibit
spread
addit
adcp
trogocytosi
anoth
potenti
outcom
fcdepend
interact
antibodi
virusinfect
cell
two
assay
develop
measur
hivsivspecif
adcc
respons
shown
also
detect
antibodymedi
interact
monocyt
virusinfect
proteinco
cell
assay
use
fluoresc
dye
label
infect
proteinco
target
cell
flow
cytometr
analysi
cell
popul
incub
target
cell
antivir
antibodi
innat
effector
cell
identifi
cell
present
effector
cell
popul
acquir
fluoresc
dye
use
label
target
cell
transfer
target
cell
membran
trogocytosi
andor
adcp
cell
cell
fragment
recent
vitro
trogocytosi
assay
develop
use
flow
cytometri
specif
measur
transfer
membran
fragment
cell
line
monocyt
cell
line
relationship
trogocytosi
phagocytosi
remain
unclear
may
two
process
mutual
exclus
trogocytosi
occur
result
abort
phagocytosi
altern
antibodydepend
trogocytosi
may
repres
altern
mechan
elimin
target
cell
present
role
trogocytosi
immun
respons
viru
infect
known
addit
research
need
determin
process
impact
viru
pathogenesi
explor
potenti
integr
adcp
signific
barrier
translat
fc
effector
function
anim
human
notabl
differ
fcfc
receptor
system
rhesu
mice
human
differ
mous
human
fcfc
receptor
system
review
previous
rhesu
human
fcfc
receptor
system
might
expect
similar
remain
substanti
differ
fc
differ
appar
compar
iga
igg
subclass
rhesu
macaqu
human
figur
rhesu
macaqu
one
iga
gene
wherea
human
two
iga
gene
rhesu
macaqu
human
four
igg
subclass
rhesu
igg
structur
function
analog
human
fact
rhesu
igg
subclass
genet
similar
human
homologu
figur
divers
germlin
immunoglobulin
gene
higher
rhesu
macaqu
human
structur
differ
rhesu
human
antibodi
best
exemplifi
subclass
human
ch
domain
encod
repeat
hing
region
exon
result
hing
approxim
four
time
longer
number
amino
acid
human
figur
exon
duplic
hing
elong
rhesu
macaqu
structur
hing
dictat
flexibl
antibodi
therefor
impact
biolog
function
implic
translat
studi
perform
human
rhesu
macaqu
exampl
vaccineelicit
hivspecif
identifi
correl
reduc
risk
infect
clinic
trial
vitro
studi
demonstr
higher
adcp
activ
hiv
monoclon
antibodi
compar
igg
subclass
given
differ
human
rhesu
unlik
preclin
studi
perform
rhesu
model
would
predict
vaccineelicit
could
play
crucial
role
reduc
risk
hiv
infect
observ
caveat
must
consid
use
anim
model
also
differ
human
rhesu
macaqu
antibodi
interact
fc
receptor
instanc
rhesu
retain
strong
bind
fc
receptor
wherea
human
sever
attenu
bind
thu
similar
fc
receptor
interact
effector
function
across
rhesu
igg
compar
observ
human
suggest
rhesu
macaqu
use
igg
subclass
tune
antibodi
respons
extent
human
highlight
need
caution
compar
subclass
profil
humor
respons
across
speci
addit
rhesu
macaqu
fc
receptor
highli
polymorph
human
fc
receptor
function
implic
mani
polymorph
yet
defin
importantli
rhesu
human
fc
fc
receptor
crossreact
bind
antibodi
bind
differ
human
rhesu
macaqu
compar
antibodi
fc
mutant
suggest
antibodi
may
behav
similarli
human
rhesu
macaqu
commonli
engag
adcp
despit
differ
preliminari
data
indic
remain
crossreact
level
function
homolog
phagocytosi
human
rhesu
macaqu
similar
rank
order
phagocytosi
activ
across
speci
human
igg
iga
isotypessubclass
test
human
rhesu
monocyt
neutrophil
pollara
et
al
unpublish
observ
studi
requir
interact
fc
fc
receptor
differ
speci
effect
phagocytosi
subsequ
effect
phagocytosi
determin
find
preclin
studi
translat
passiv
immunotherapi
may
simpler
model
sinc
appear
function
homolog
phagocytosi
human
rhesu
system
human
ig
use
human
mice
also
valuabl
type
studi
specif
mous
model
develop
smith
collabor
laboratori
dr
jeffrey
ravetch
expect
provid
util
model
mous
receptor
gene
delet
human
receptor
transgen
insert
result
mice
express
function
human
receptor
type
cell
level
found
human
primari
limit
model
human
receptor
express
thu
fc
receptor
neonat
type
ii
fc
receptor
fcbind
protein
remain
nativ
mous
form
moreov
repeat
infus
human
igg
result
develop
antihuman
igg
antibodi
mice
adcp
fc
receptordepend
function
antibodi
like
common
immun
respons
elicit
viru
infect
respons
vaccin
importantli
substanti
evid
support
adcp
contribut
either
protect
infect
reduct
diseas
sever
divers
type
virus
case
like
adcp
work
tandem
addit
fcindepend
fcdepend
antivir
activ
part
effect
polyfunct
humor
respons
fact
mani
virus
demonstr
antibodydepend
correl
protect
highli
like
adcp
involv
perhap
thoroughli
explor
addit
investig
role
adcp
protect
viral
respons
specif
viru
epitop
target
adcp
antibodi
may
provid
insight
strategi
ration
vaccin
design
elicit
type
antibodi
respons
avoid
deleteri
ade
activ
addit
identifi
type
phagocyt
fc
receptor
involv
adcp
site
viru
infect
within
tissu
throughout
cours
infect
viru
clearanc
remain
understudi
aspect
host
viru
interact
final
adcp
assay
use
measur
immun
respons
vitro
quantifi
uptak
viru
subunit
virion
case
infect
cell
remain
gap
knowledg
regard
outcom
phagocytosi
research
area
could
determin
protect
adcp
depend
clearanc
elimin
viru
viru
infect
cell
potenti
subsequ
immun
respons
via
antigen
present
immun
signal
understand
adcp
grow
like
approach
success
leverag
import
immun
respons
improv
antivir
immun
discov
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
